Applied DNA to Webcast 2019 Annual Stockholders’ Meeting

STONY BROOK, N.Y.–(BUSINESS WIRE)–Applied
DNA Sciences, Inc. (NASDAQ: APDN), will hold its 2019 Annual Meeting
of Stockholders on Thursday, May 16, 2019. On that date, the company
will provide an audio-only live webcast of the meeting beginning at
10:00 AM ET. Slide presentations accompanying the webcast will be
available for download at that time on the ‘Events and Presentations’
portion of the ‘Investors’
page to the company’s website.

To register for the webcast on May 16, please visit: https://services.choruscall.com/links/apdn190516.html

A telephonic replay of the Meeting will be available through 5:00 PM ET
on Thursday, May 30, 2019:

• Replay dial-in: 1-877-344-7529
• International replay: 1-412-317-0088
• Access code: 10130086

An archived video bundle of the Meeting will be made available within 48
hours of the Meeting on the ‘Events and Presentations’ portion of the ‘Investors’
page to the company’s website.

About Applied DNA Sciences

Applied DNA is a provider of molecular technologies that enable supply
chain security, anti-counterfeiting and anti-theft technology, product
genotyping and pre-clinical nucleic acid-based therapeutic drug
candidates.

Applied DNA makes life real and safe by providing innovative,
molecular-based technology solutions and services that can help protect
products, brands, entire supply chains, and intellectual property of
companies, governments and consumers from theft, counterfeiting, fraud
and diversion.

Visit adnas.com
for more information. Follow us on Twitter and LinkedIn. Join our
mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are
listed under the symbol APDNW.

Forward Looking Statements

The statements made by Applied DNA in this press release may be
“forward-looking” in nature within the meaning of the Private Securities
Litigation Act of 1995. Forward-looking statements describe Applied
DNA’s future plans, projections, strategies and expectations, and are
based on assumptions and involve a number of risks and uncertainties,
many of which are beyond the control of Applied DNA including the
substantial doubt relating to the Company’s ability to continue as a
going concern. Actual results could differ materially from those
projected due to its history of net losses, limited financial resources,
limited market acceptance, the uncertainties inherent in research and
development, future clinical data and analysis, including whether any of
Applied DNA’s product candidates will advance further in preclinical
research or clinical trial process, including receiving clearance from
the U.S. Food and Drug Administration or equivalent foreign regulatory
agencies to conduct clinical trials and whether and when, if at all,
they will receive final approval from the U.S. FDA or equivalent foreign
regulatory agencies, shifting enforcement priorities of US federal laws
relating to cannabis, ability to maintain its NASDAQ listing, and
various other factors detailed from time to time in Applied DNA’s SEC
reports and filings, including our Annual Report on Form 10-K filed on
December 18, 2018 and our subsequent quarterly reports on 10-Q filed on
February 7, 2019 and May 9, 2019, and other reports we file with the
SEC, which are available at www.sec.gov.
Applied DNA undertakes no obligation to update publicly any
forward-looking statements to reflect new information, events or
circumstances after the date hereof to reflect the occurrence of
unanticipated events, unless otherwise required by law.

Contacts

Investors: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, [email protected]
Web:
www.adnas.com
Twitter:
@APDN